November 2019 prioritisation decisions

For this round NHSE announced there was sufficient available resource to fund treatments falling in level 1 and 2 (temozolomide and dexrazoxane) but insufficient remaining resource to fund all but two policies falling in level 3 (human coagulation factor X and canakinumab).

SPS commentary:

The following have been funded:

 

  • Level 1: Temozolomide as adjuvant treatment for people with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (adults)

 

  • Level 2: Dexrazoxane for preventing cardiotoxicity in children and young people (< 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer

 

  • Level 3: Human coagulation factor X for hereditary factor X deficiency (all ages) and Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)

 

Ranked as level 4, mercaptamine hydrochloride for corneal cystine deposits in people aged older than 2 years and Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease, will not be funded.

 

NHS England